APA

Trarbach T., Moehler M., Heinemann V., Köhne C., Przyborek M., Schulz C., Sneller V., Gallant G. & Kanzler S. (20100223). Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. : British journal of cancer.

Chicago

Trarbach T, Moehler M, Heinemann V, Köhne C-H, Przyborek M, Schulz C, Sneller V, Gallant G and Kanzler S. 20100223. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. : British journal of cancer.

Harvard

Trarbach T., Moehler M., Heinemann V., Köhne C., Przyborek M., Schulz C., Sneller V., Gallant G. and Kanzler S. (20100223). Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. : British journal of cancer.

MLA

Trarbach T, Moehler M, Heinemann V, Köhne C-H, Przyborek M, Schulz C, Sneller V, Gallant G and Kanzler S. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. : British journal of cancer. 20100223.